Plus 5 Newsletter Example

SPONSOR

EDITOR’S PICKS

5. Vital Therapies lowers the bar with 2nd IPO try

Vital Therapies lowers the bar in its 2nd try at an initial public offering, aiming to raise up to $68 million this time around. Read more

4. ReliantHeart goes head-to-head with Thoratec to aim for U.S. LVAD market

ReliantHeart touts study data finding that its HeartAssist5 left ventricular assist device poses a lower risk of blood clots and damage compared with Thoratec’s HeartMate II. Read more

SPONSOR

Obsessed with perfection?

So is Resonetics, with more than 25 years of experience laser micromachining polymers for the life sciences market, where products can require features as small as 1 micron. Whether laser machining the world’s most advanced stents or drilling holes small enough to filter individual blood cells, we’re proud to be a bit obsessed.

Reduce your time to market with our 8,000-sq. ft. Lightspeed ADL™ application development lab.
Rely on our high-volume production with more than 50 lasers (excimer, femtosecond, picosecond, DPSS, CO2) and automated material handling and inspection.
Trust our reliability with Class 8 cleanroom manufacturing, robust validations, and certified Black Belts.

Come visit us in New Hampshire or call us to learn what our obsession with perfection can mean for your next product launch. 603.886.6772.

3. Deerfield raises $1.6B healthcare fund

Deerfield Management says it’s drummed up an investment fund worth $1.6 billion, targeted at investments in healthcare companies. Read more

2. PAD: Medtronic’s In.Pact Admiral drug-eluting balloon bests Bard’s Lutonix at 6 months

Results from a clinical trial of Medtronic’s In.Pact Admiral drug-eluting balloon for peripheral artery disease show lower target lesion revascularization rates than rival C.R. Bard’s Lutonix DEB. Read more

SPONSOR

Get more out of MassDevice with our daily newsletter

Our daily newsletter gets you caught up on all the mission-critical news you need in medtech. Sign up for our free newsletter today.

Subscribe Now!

Get mobile with MassDevice

1. Intuitive Surgical drops on limp Q1 prelims

Intuitive Surgical lost some Wall Street favor after posting dim preliminary results for its 1st quarter of 2014.

The preliminary results came the same day as a blunt editorial from Pennsylvania urologist Dr. Benjamin Davies excoriating Intuitive over the release of its latest da Vinci surgical robot. Read more

GOT A GREAT STORY? DROP US A LINE